ArticleJournal of orthopaedic surgery and research2026
miR-326 promotes osteogenic differentiation of bone marrow mesenchymal stem cells by targeting NAT10.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAbnormal osteogenic differentiation of BMSCs is a core factor in osteoporosis (OP). This study investigates how miR-326 regulates osteogenic differentiation of hBMSCs by targeting NAT10, thereby influencing OP pathogenesis.
methodSerum miR-326 levels were measured using RT-qPCR. Its diagnostic value for OP was assessed by ROC analysis, and its correlation with bone mineral density (BMD) was examined. Using a dexamethasone (DEX)-induced hBMSC OP model, we evaluated the effects of miR-326 on osteogenesis (RT-qPCR), cell viability (CCK-8 assay), and inflammation (ELISA). The miR-326-NAT10 interaction was confirmed by dual-luciferase assay. A rescue experiment with co-transfection verified their functional relationship.
resultsMiR-326 levels in OP patient serum were significantly decreased, and the area under the ROC curve demonstrated excellent diagnostic performance The OP group exhibited significantly lower BMD, which was positively correlated with reduced miR-326 expression. In DEX-induced hBMSCs, miR-326 overexpression promoted osteogenesis by upregulating key markers, enhanced cell viability, and attenuated inflammation. Dual-luciferase assays confirmed NAT10 as a direct target of miR-326. NAT10 was upregulated in OP patients and negatively correlated with miR-326, and oe-NAT10 rescued the pro-osteogenic and anti-inflammatory effects of miR-326.
conclusionsmiR-326 is downregulated in the OP and can serve as a potential diagnostic biomarker for OP. miR-326 promotes osteogenic differentiation of hBMSCs and inhibits inflammatory responses by targeting NAT10, exerting a protective role in the pathogenesis of OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.